NCT03275363

The University of Hong Kong Neurocognitive Disorder Cohort

Status unknown Last updated 7 September 2017

What this trial tests

trial testing Neurocognitive battery in Neurocognitive Disorder in 500 participants. Status unknown.

Timeline

1 September 2014

Primary endpoint
1 January 2022

4 January 2022

Quick facts

Lead sponsor	The University of Hong Kong
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 September 2014
Primary completion	1 January 2022
Estimated completion	4 January 2022
Sites	1 location across Hong Kong

Drugs / interventions tested

• Neurocognitive battery
• MRI — full drug profile →
• Blood tests — full drug profile →
• EEG with event-related potential (ERP)
• Amyloid PET CT

Conditions studied

• Neurocognitive Disorder — all drugs for Neurocognitive Disorder →
• Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
• Alzheimer Dementia — all drugs for Alzheimer Dementia →
• Vascular Dementia — all drugs for Vascular Dementia →

Sponsor

The University of Hong Kong

Who can join

65 and older, any sex, with Neurocognitive Disorder or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The HKU Neurocognitive Disorder (NCD) Cohort is a hospital-based, prospective, observational study of older HK Chinese adults with cognitive impairment, with a special focus on studying patients with subjective cognitive decline and mild cognitive impairment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Exosome Processing and Characterization Approaches for Research and Technology Development.
   Lai JJ, Chau ZL, Chen SY, Hill JJ, et al · · 2022 · cited 385× · PMID 35332686 · DOI 10.1002/advs.202103222
2. Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.
   Huda MN, Nafiujjaman M, Deaguero IG, Okonkwo J, et al · · 2021 · cited 160× · PMID 33988964 · DOI 10.1021/acsbiomaterials.1c00217
3. Biomarker potential of brain-secreted extracellular vesicles in blood in Alzheimer's disease.
   Badhwar A, Haqqani AS. · · 2020 · cited 68× · PMID 32211497 · DOI 10.1002/dad2.12001
4. Global trend in exosome isolation and application: an update concept in management of diseases.
   Omrani M, Beyrampour-Basmenj H, Jahanban-Esfahlan R, Talebi M, et al · · 2024 · cited 55× · PMID 37166542 · DOI 10.1007/s11010-023-04756-6
5. Emerging Role of Extracellular Vesicles as Biomarkers in Neurodegenerative Diseases and Their Clinical and Therapeutic Potential in Central Nervous System Pathologies.
   Malaguarnera M, Cabrera-Pastor A. · · 2024 · cited 30× · PMID 39337560 · DOI 10.3390/ijms251810068
6. The Landscape of Exosomes Biogenesis to Clinical Applications.
   Al-Madhagi H. · · 2024 · cited 28× · PMID 38681093 · DOI 10.2147/ijn.s463296
7. Exosomes in neuron-glia communication: A review on neurodegeneration.
   Akbari-Gharalari N, Khodakarimi S, Nezhadshahmohammad F, Karimipour M, et al · · 2024 · cited 13× · PMID 39296798 · DOI 10.34172/bi.2023.30153
8. Basic Pathogenic Mechanisms and Epigenetic Players Promoted by Extracellular Vesicles in Vascular Damage.
   Schiano C, Balbi C, de Nigris F, Napoli C. · · 2023 · cited 7× · PMID 37108672 · DOI 10.3390/ijms24087509